PPARs and Myocardial Infarction

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 16

PMID 33322384

Citations 10

Authors

Kay-Dietrich Wagner

Nicole Wagner

Affiliations

Soon will be listed here.

Abstract

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. They are ligand-activated transcription factors and exist in three different isoforms, PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs regulate a variety of functions, including glucose and lipid homeostasis, inflammation, and development. They exhibit tissue and cell type-specific expression patterns and functions. Besides the established notion of the therapeutic potential of PPAR agonists for the treatment of glucose and lipid disorders, more recent data propose specific PPAR ligands as potential therapies for cardiovascular diseases. In this review, we focus on the knowledge of PPAR function in myocardial infarction, a severe pathological condition for which therapeutic use of PPAR modulation has been suggested.

Citing Articles

Interplay between energy metabolism and NADPH oxidase-mediated pathophysiology in cardiovascular diseases.

Jie H, Zhang J, Wu S, Yu L, Li S, Dong B Front Pharmacol. 2025; 15:1503824.

PMID: 39867658 PMC: 11757639. DOI: 10.3389/fphar.2024.1503824.

Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical Evidence-A Narrative Review.

Rubio-Ruiz M, Plata-Corona J, Soria-Castro E, Diaz-Juarez J, Sanchez-Aguilar M Cells. 2024; 13(17.

PMID: 39273057 PMC: 11394383. DOI: 10.3390/cells13171488.

PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments.

Skoczynska A, Oldakowska M, Dobosz A, Adamiec R, Gritskevich S, Jonkisz A Biomolecules. 2024; 14(7).

PMID: 39062500 PMC: 11275227. DOI: 10.3390/biom14070786.

VSP-2 attenuates secretion of inflammatory cytokines induced by LPS in BV2 cells by mediating the PPARγNF-κB signaling pathway.

Cui J, Xu L, Sun Y, Dai L, Mo Y, Yun K Open Life Sci. 2024; 19(1):20220861.

PMID: 38681727 PMC: 11049741. DOI: 10.1515/biol-2022-0861.

Valerenic acid attenuates pathological myocardial hypertrophy by promoting the utilization of multiple substrates in the mitochondrial energy metabolism.

Liu T, Chen X, Sun Q, Li J, Wang Q, Wei P J Adv Res. 2024; 68:241-256.

PMID: 38373650 PMC: 11785575. DOI: 10.1016/j.jare.2024.02.008.

References

Reinhard W, Stark K, Sedlacek K, Fischer M, Baessler A, Neureuther K . Association between PPARalpha gene polymorphisms and myocardial infarction. Clin Sci (Lond). 2008; 115(10):301-8. DOI: 10.1042/CS20070391. View

Wagner N, Wagner K . PPARs and Angiogenesis-Implications in Pathology. Int J Mol Sci. 2020; 21(16). PMC: 7461101. DOI: 10.3390/ijms21165723. View

Nissen S, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-71. DOI: 10.1056/NEJMoa072761. View

Benson S, Pershadsingh H, Ho C, Chittiboyina A, Desai P, Pravenec M . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43(5):993-1002. DOI: 10.1161/01.HYP.0000123072.34629.57. View

Chen X, Liu Z, Xue Y, Chen X . Dual PPARα/γ ligand TZD18 improves myocardial metabolic remodeling after myocardial infarction in rats. Eur Rev Med Pharmacol Sci. 2017; 21(24):5765-5773. DOI: 10.26355/eurrev_201712_14023. View

Lee J, Hu Q, Nakamura Y, Wang X, Zhang X, Zhu X . Open-chest 31P magnetic resonance spectroscopy of mouse heart at 4.7 Tesla. J Magn Reson Imaging. 2006; 24(6):1269-76. DOI: 10.1002/jmri.20766. View

Tao L, Wang Y, Gao E, Zhang H, Yuan Y, Lau W . Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res. 2009; 106(2):409-17. PMC: 2818803. DOI: 10.1161/CIRCRESAHA.109.211797. View

Goyal S, Arora S, Mittal R, Joshi S, Nag T, Ray R . Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. Eur J Pharmacol. 2009; 619(1-3):75-84. DOI: 10.1016/j.ejphar.2009.07.026. View

Rani N, Arya D . Chrysin rescues rat myocardium from ischemia-reperfusion injury via PPAR-γ/Nrf2 activation. Eur J Pharmacol. 2020; 883:173389. DOI: 10.1016/j.ejphar.2020.173389. View

10.

Meng C, Guo Z, Li D, Li H, He J, Wen D . Preventive effect of hesperidin modulates inflammatory responses and antioxidant status following acute myocardial infarction through the expression of PPAR‑γ and Bcl‑2 in model mice. Mol Med Rep. 2017; 17(1):1261-1268. DOI: 10.3892/mmr.2017.7981. View

11.

Hou J, Wang L, Hou J, Guo T, Xing Y, Zheng S . Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-β1/Smads Signaling in a Rat Model of Myocardial Infarction. Stem Cell Rev Rep. 2015; 11(6):885-99. DOI: 10.1007/s12015-015-9615-7. View

12.

Delea T, Edelsberg J, Hagiwara M, Oster G, Phillips L . Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003; 26(11):2983-9. DOI: 10.2337/diacare.26.11.2983. View

13.

Garg S, Irfan Khan S, Malhotra R, Sharma M, Kumar M, Kaur P . The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR-γ in a murine model of myocardial infarction. Arch Biochem Biophys. 2020; 694:108572. DOI: 10.1016/j.abb.2020.108572. View

14.

Goldenberg I, Benderly M, Goldbourt U . Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol. 2008; 51(4):459-65. DOI: 10.1016/j.jacc.2007.09.048. View

15.

Wagner K, Wagner N . Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2009; 125(3):423-35. DOI: 10.1016/j.pharmthera.2009.12.001. View

16.

Kaul S, Bolger A, Herrington D, Giugliano R, Eckel R . Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010; 121(16):1868-77. DOI: 10.1161/CIR.0b013e3181d34114. View

17.

Lincoff A, Tardif J, Schwartz G, Nicholls S, Ryden L, Neal B . Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014; 311(15):1515-25. DOI: 10.1001/jama.2014.3321. View

18.

Mikami D, Kimura H, Kamiyama K, Torii K, Kasuno K, Takahashi N . Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells. Hypertens Res. 2013; 37(5):422-31. DOI: 10.1038/hr.2013.157. View

19.

Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C . Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res. 2009; 83(1):61-71. DOI: 10.1093/cvr/cvp106. View

20.

Kostic I, Fidalgo-Carvalho I, Aday S, Vazao H, Carvalheiro T, Graos M . Lysophosphatidic acid enhances survival of human CD34(+) cells in ischemic conditions. Sci Rep. 2015; 5:16406. PMC: 4639756. DOI: 10.1038/srep16406. View